Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Stock Up 3.7 %

NASDAQ AXDX opened at $1.11 on Friday. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $4.28. The firm has a market cap of $27.80 million, a P/E ratio of -0.39 and a beta of 0.56. The company’s 50 day moving average is $1.63 and its 200-day moving average is $1.54.

Insider Activity at Accelerate Diagnostics

In other news, Director John Patience acquired 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average cost of $1.57 per share, with a total value of $314,000.00. Following the acquisition, the director now owns 653,224 shares in the company, valued at approximately $1,025,561.68. This represents a 44.13 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 43.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. Institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.